ZEO ScientifiX

ZEO ScientifiX Current Assets

The Current Assets of ZEO ScientifiX (ZEOX) as of Nov 2, 2026 is 423,000.00 USD. In the previous year, Current Assets was 429,000.00 USD — a change of -1.40% (lower).

Current Assets

423,000.00USD

YoY

-1.40%

Last updated:

Current Assets of ZEO ScientifiX is 2025 423,000.00 USD. Current Assets of ZEO ScientifiX was 2024 429,000.00 USD. It decreases by -1.40% lower compared to the previous year.

The ZEO ScientifiX Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2018
106,200.00 USD
Jan 1, 2019
26,000.00 USD
Jan 1, 2020
176,211.00 USD
Jan 1, 2021
339,027.00 USD
Jan 1, 2022
440,010.00 USD
Jan 1, 2023
340,183.00 USD
Jan 1, 2024
429,000.00 USD
Jan 1, 2025
423,000.00 USD
The ZEO ScientifiX Current Assets history
YEARCurrent AssetsYoY
423,000.00USD-1.40%
429,000.00USD+26.11%
340,183.00USD-22.69%
440,010.00USD+29.79%
339,027.00USD+92.40%
176,211.00USD+577.73%
26,000.00USD-75.52%
106,200.00USD-62.23%
281,200.00USD+655.91%
37,200.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ZEO ScientifiX Stock analysis

What does ZEO ScientifiX do? Organicell Regenerative Medicine Inc generates revenue through its clinical-stage biopharmaceutical products, primarily focusing on regenerative medicine solutions. The company's leading product, Zofin (Organicell Flow), is an acellular biologic therapeutic derived from perinatal sources, containing over 300 growth factors, cytokines, chemokines, and 102 unique microRNAs. This product is administered through doctors and clinics in the healthcare industry, targeting degenerative diseases. The company has secured FDA approvals including IND and eIND, along with IRB authorizations, enabling its therapeutic applications. The company operates within the biotechnology sector, developing biological therapeutics for degenerative conditions. Zofin (Organicell Flow) serves as the core product, leveraging natural microRNAs and exosomes from perinatal tissues without additional substances. Healthcare providers and clinics are the primary buyers of this therapeutic, utilizing it for patient treatments under FDA-approved protocols. The product's unique composition supports its application in regenerative medicine, differentiating it in the market. Organicell Regenerative Medicine Inc's business model centers on the development and commercialization of Zofin (Organicell Flow), which is used in clinical settings for degenerative disease treatment. The company's focus on FDA-approved pathways through IND and eIND approvals ensures regulatory compliance for its product distribution. Healthcare professionals and clinics are the key segments purchasing the product, driven by its therapeutic benefits and natural composition derived from perinatal sources. ZEO ScientifiX is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ZEO ScientifiX stock

Current Assets of ZEO ScientifiX is 423,000.00 USD in 2025.

Current Assets of ZEO ScientifiX changed from 429,000.00 USD to 423,000.00 USD, representing a -1.40% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Assets ZEO ScientifiX since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's ZEO ScientifiX historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — ZEO ScientifiX

All Key Metrics — ZEO ScientifiX